Activist DOMA Escalates Proxy Battle, Alleges "Value Destruction" and Misleading Patent Claims

summarizeSummary

Activist investor DOMA Perpetual Capital Management, holding a 7.5% stake, has intensified its proxy battle against Pacira BioSciences, accusing the current board of overseeing a decade of value destruction, misleading shareholders on patent protection, and refusing to explore a sale.

check_boxKey Events · Corporate Governance and Compliance · PCRX

• Proxy Battle Escalation

  Activist DOMA Perpetual Capital Management (7.5% stake) intensified its campaign against Pacira's board ahead of the June 9 annual meeting.

• Allegations of Value Destruction

  DOMA claims the current board has overseen a decade of poor shareholder returns, with the stock price down across all recent periods.

• Patent Protection Concerns

  DOMA alleges management is misleading investors about the strength of its patent portfolio for EXPAREL, which generates 80% of company revenue, and minimizing the risk of further legal losses.

• Call for Strategic Review

  DOMA contends the board is refusing to explore a company sale to protect their own positions, putting personal interests ahead of shareholder value.

auto_awesomeAnalysis · PCRX · Life Sciences

This filing from activist investor DOMA Perpetual Capital Management significantly escalates the ongoing proxy battle by presenting detailed criticisms of Pacira's management and board. DOMA alleges a decade of poor shareholder returns, misrepresentation of patent strength for EXPAREL (which accounts for 80% of revenue), and a failure to explore strategic alternatives like a sale. These claims, if gaining traction with shareholders, could lead to a change in board composition and a fundamental shift in the company's strategic direction, including a potential sale process. The annual meeting on June 9, 2026, will be a critical event.